Sage Therapeutics Inc SAGE
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit
-
Sage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program
-
Class Action Filed Against Sage Therapeutics, Inc. (SAGE) Seeking Recovery for Investors - Contact The Gross Law Firm
-
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SAGE
-
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
-
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
-
SAGE Investors Have Opportunity to Lead Sage Therapeutics, Inc. Securities Fraud Lawsuit
Trading Information
- Previous Close Price
- $7.02
- Day Range
- $7.00–7.23
- 52-Week Range
- $6.98–28.26
- Bid/Ask
- $7.00 / $7.32
- Market Cap
- $437.73 Mil
- Volume/Avg
- 462,923 / 812,583
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.34
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 487
- Website
- https://www.sagerx.com
Comparables
Valuation
|
Metric
|
SAGE
|
TRVI
|
UTHR
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | 18.32 |
Price/Book Value | 0.68 | 3.38 | 2.80 |
Price/Sales | 4.34 | — | 6.76 |
Price/Cash Flow | — | — | 14.49 |
Price/Earnings
SAGE
TRVI
UTHR
Financial Strength
|
Metric
|
SAGE
|
TRVI
|
UTHR
|
|---|---|---|---|
Quick Ratio | 9.51 | 10.29 | 3.92 |
Current Ratio | 9.95 | 10.68 | 4.35 |
Interest Coverage | — | −4,780.89 | 22.67 |
Quick Ratio
SAGE
TRVI
UTHR
Profitability
|
Metric
|
SAGE
|
TRVI
|
UTHR
|
|---|---|---|---|
Return on Assets (Normalized) | −38.82% | −40.88% | 16.95% |
Return on Equity (Normalized) | −43.21% | −44.19% | 20.53% |
Return on Invested Capital (Normalized) | −47.65% | −48.62% | 16.62% |
Return on Assets
SAGE
TRVI
UTHR
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Pwghdhxbw | Gxlwt | $566.0 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Jfpjydjf | Frvhj | $119.2 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Drltrdbw | Hwdlpw | $113.7 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Ncnlchy | Klnhwvj | $35.0 Bil | |||
| argenx SE ADR
ARGX
| Hshwhlkdy | Mnnf | $32.5 Bil | |||
| BioNTech SE ADR
BNTX
| Jbrhlnks | Lts | $27.5 Bil | |||
| Moderna Inc
MRNA
| Fwjzvdtr | Dqch | $24.5 Bil | |||
| United Therapeutics Corp
UTHR
| Hxtdcptnn | Bhmr | $16.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qpjhyrvz | Dxbzyw | $13.1 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Npgwjnhzw | Fsqvp | $12.4 Bil |
United States